Oculis Holding AG (OCS) stock
Close on Nov 13, 2026Market cap $459.08MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- CHF 376.08M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -17.71%
Fundamentals
- EPS, diluted
- -1.89 CHF
- Free cash flow
- -CHF 66.61M
- Diluted shares
- 61M
Trading
- Previous close
- $7.50
- Open
- $7.51
- Day's range
- $7.28 – $7.68
- Volume
- 183,977
- Average volume (20 days)
- 313,738
- Beta (5 years)
- 0.43
- RSI (14 days)
- 44.3
- Volatility (1 year)
- 68.1%
- Relative volume
- 0.66×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | OCS | S&P 500 | Difference | OCS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.3% | -3.0% | +3.3 pts | ||
| 3 months | -40.4% | -2.8% | −37.6 pts | ||
| Year to date | -61.7% | +11.5% | −73.2 pts | ||
| 1 year | -60.4% | +13.5% | −73.9 pts | ||
| 3 years | -22.0% | +77.7% | −99.7 pts | -8.0% | +21.1% |
| 5 years | -21.5% | +72.6% | −94.1 pts | -4.7% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025, CHF
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Oculis filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Oculis
Pharmaceutical Preparations
Oculis Holding AG operates as a clinical-stage biopharmaceutical organization engaged in the discovery, research, and development of pharmaceutical product candidates. The enterprise conducts preclinical evaluations, clinical trials, and regulatory compliance activities to advance medical treatments based on its scientific technology and in-licensed assets. It focuses on advancing a pipeline of candidate therapies toward commercial readiness and manufacturing. The company's intended recipients and end users include patient groups with targeted therapeutic needs, while its direct commercial relationships involve academic institutions, healthcare entities, and corporate research partners.
Company profile, executives and historyOculis stock: common questions
What is Oculis's stock price?
OCS closed at $7.64 on Nov 13, 2026, up 1.87% on the day.
What is Oculis's market cap?
Oculis was worth $459.08M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is OCS's P/E ratio?
Oculis lost money over fiscal 2025 (diluted EPS -1.89 CHF), so it has no meaningful P/E ratio.
Does Oculis pay a dividend?
No. Oculis has not paid a cash dividend over the last twelve months.
How has OCS stock performed over the past year?
Including dividends, OCS returned -60.4% over the past year, against +13.5% for the S&P 500.
Who are Oculis's competitors?
Companies most similar to Oculis by business, industry and size include NBP, XTLB, OCEA, PRQR, ANL.
See a number that looks wrong?